1. Home
  2. CHCT vs DSGN Comparison

CHCT vs DSGN Comparison

Compare CHCT & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Community Healthcare Trust Incorporated

CHCT

Community Healthcare Trust Incorporated

HOLD

Current Price

$15.26

Market Cap

410.6M

Sector

Real Estate

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$9.95

Market Cap

418.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHCT
DSGN
Founded
2014
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
410.6M
418.1M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
CHCT
DSGN
Price
$15.26
$9.95
Analyst Decision
Buy
Buy
Analyst Count
2
2
Target Price
$18.00
$13.50
AVG Volume (30 Days)
323.0K
538.4K
Earning Date
10-28-2025
11-05-2025
Dividend Yield
12.43%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$119,547,000.00
N/A
Revenue This Year
$6.97
N/A
Revenue Next Year
$5.98
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.40
N/A
52 Week Low
$13.23
$2.60
52 Week High
$20.87
$10.31

Technical Indicators

Market Signals
Indicator
CHCT
DSGN
Relative Strength Index (RSI) 53.39 71.98
Support Level $15.18 $8.58
Resistance Level $15.91 $9.85
Average True Range (ATR) 0.45 0.66
MACD 0.02 0.13
Stochastic Oscillator 56.77 86.62

Price Performance

Historical Comparison
CHCT
DSGN

About CHCT Community Healthcare Trust Incorporated

Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers in non-urban markets. The company derives majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: